Julia Talsma, Content Channel Director
Julia Talsma is lead editor for Drug Topics magazine.
Cardinal Health to buy drug distributor for $1.1 billion
Cardinal Health announced that it plans to purchase The Harvard Drug Group, based in Livonia, Mich. The deal, worth $1.115 billion, is expected to close by the beginning of the company’s fiscal year 2016.
Current approach to prevent hip fracture in elderly not working
It’s time to re-examine the current assumption that a diagnosis and subsequent treatment of osteoporosis will prevent hip fractures in the elderly, according to a recent report in the BMJ.
Bedside delivery service pilot program builds pharmacists’ role
A new bedside delivery service of outpatient medications is being tested at an acute care facility in Cincinnati, Ohio.
New peppermint oil formulation helps quiet IBS symptoms
A new formulation of peppermint oil has been shown to relieve severe IBS symptoms in adults.
Walgreens Infusion Services now independent with private equity partner
The new independent company, Option Care, sees opportunity for growth in the $14 billion alternate site infusion market.
Higher oncology costs driven by practice setting
The good news is that the five-year relative survival rates for major cancers are rising. The bad news is that patient out-of-pocket costs associated with IV cancer drugs have also increased as physician-owned practices have been purchased by hospitals, according to a recent report from IMS Institute for Healthcare Informatics.
DEA needs better management of quota process for controlled substances
The Drug Enforcement Agency (DEA), responsible for setting quotas of controlled substances, has not responded to manufacturers’ applications for these quotas in a timely fashion—and this has contributed to the shortage of controlled substances over the last decade, according to a recent GAO report.
Sale of biosimilar Zarxio delayed until at least June 3
Although the biosimilar Zarxio (filgrastim-sndz,) was approved in March, the manufacturer, Sandoz/Novartis, has been delayed from selling the drug until a patent dispute with Amgen is resolved.
New biologic to control bleeding for hemophilia B patients
At the end of April, FDA approved a new biologic to help prevent and control bleeding in patients with hemophilia B who are 12 years and older. It also is approved for use in perioperative management in this patient population.
A needle-free approach will help control postoperative pain in hospital
FDA has approved the first needle-free, patient-controlled fentanyl delivery system for the management of postoperative pain in adults requiring opioid pain relief in the hospital.

Poll